The Week in Review: February 2 – February 9, 2018

Friday, February 9, 2018 News Recap: Epidemiology: CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. #EASLmono: Expanding the conversation on hepatitis elimination. The recent European...

CTAC Launches Campaign to End Hepatitis C in Canada

Elimination of infection in next 10 years possible through concerted action by policymakers and community leaders. TORONTO, Feb. 6, 2018 /CNW/ - The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. CTAC is once again demonstrating its commitment to

Patient Input Requested for AbbVie 2D-GT4 Combo

HepCBC is seeking individual patient input for our submission to the federal government for the first INTERFERON-FREE drug combo for GENOTYPE 4, AbbVie's "2D-GT4".ADD YOUR VOICE! We will be accepting input from anyone affected by hepatitis C (ALL GENOTYPES, not only Genotype 4) between Friday, Sept. 11 and midnight on Thursday, Sept. 25, 2015 through this confidential online form: PATIENT INPUT FORM for AbbVie 2D-GT4 Free WEBINAR about AbbVie 2D-GT4 availa

Two National Health Organizations Sign HCV Manifesto!

The Canadian Treatment Action Council (CTAC) and the Canadian AIDS Treatment and Information Exchange (CATIE) have joined three other institutional signers of the HCV MANIFESTO!  The others are ANKORS  (AIDS Network Kootenay Outreach and Support Society), the BLOOM CLINIC of  the Bramalea Community Health Centre in the Region of Peel, Ontario, and of course HepCBC Hepatitis C Education and Prevention Society. We hope many other organizations (health organi

URGENT REQUEST FOR YOUR INPUT into a new HCV drug, SIMEPREVIR

On August 22nd, 2013 the Canadian Agency for Drugs and Technologies in Health (CADTH) released a call for patient input into Janssen Inc.'s new HCV drug, SIMEPREVIR. In order to prepare our Patient Group submission by the Sept. 13th deadline, HepCBC is ASKING for INPUT from HCV+ people and caregivers from throughout Canada, by Wednesday, Sept. 11th. CLICK HERE to ADD YOUR VOICE to HepCBC's group submission which will help determine whether this new treatme